Kaʻai pono pilikino / meaʻai no ka maʻi ʻaʻai Metastatic umauma

o ka Naauao

ʻO ka maʻi ʻaʻai umauma metastatic ka maʻi ʻaʻai holomua i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino ma ʻō aku o ka umauma o ka umauma, a he wānana maikaʻi ʻole loa. ʻO ka mālama ʻana no ka neoplasm malignant umauma metastatic e neʻe nei i ka pilikino pilikino e pili ana i nā ʻano maʻi ʻaʻai. ʻO nā ʻōlelo pilikino pilikino like (nā meaʻai a me nā mea kōkua) e pili ana i nā ʻano maʻi ʻaʻai a me ka mālama ʻana e nele a pono nui ʻia e hoʻomaikaʻi i nā kūleʻa o ka kūleʻa a me ke ʻano o ke ola o ka mea maʻi maʻi. Kuhi kēia blog i nā pono, nā hemahema a me nā laʻana o ka pilikino pilikino / meaʻai (meaʻai a me nā mea kōkua) no ka maʻi ʻaʻai umauma metastatic.

Nā Kumua o ka maʻi ʻaʻai umauma

ʻO ka maʻi ʻaʻai umauma ka maʻi ʻaʻai ʻike pinepine ʻia a ʻo kekahi o nā kumu kumu o ka make ʻana e pili ana i ka maʻi ʻaʻai i nā wahine ma ka honua holoʻokoʻa. ʻO kekahi o nā subtypes maʻamau o ka maʻi ʻaʻai umauma ka mea pili i ka hormone sex, estrogen (ER) a me ka progesterone (PR) reseptor maikaʻi a me nā mea ulu ulu epidermal kanaka 2 (ERBB2, i kapa ʻia ʻo HER2) maikaʻi ʻole - (ER + / PR + / HER2- subtype). He wānana maikaʻi ka hormone subtype maikaʻi o ka maʻi ʻaʻai umauma me kahi helu ola kiʻekiʻe he 5 mau makahiki loa o 94-99% (ʻO Waks a me Lanakila, JAMA, 2019). ʻO nā ʻano ʻē aʻe o ka umauma Ka maʻi 'aʻai ʻO ia ka ʻano ʻano ʻano ʻino ʻole o ka hormone receptor, HER2 maikaʻi a me ka triple negative breast cancer (TNBC) subtype ʻo ia ka ER, PR a me HER2 ʻino. Loaʻa i ka subtype TNBC ka wānana ʻino loa a me ke kūlana kiʻekiʻe loa o ka neʻe ʻana i ka maʻi hope loa i hoʻonui ʻia a laha i nā wahi ʻē aʻe o ke kino.

ʻO ka maʻi maʻi Metastatic Breast Cancer ka holomua loa, pae IV maʻi ʻaʻai i hohola ʻia i nā ʻāpana ʻē aʻe o ke kino (ʻo ka pinepine, nā iwi, nā akemāmā, ka ate a me ka lolo). Aia he 6% wale nō o nā wahine i ʻike ʻia me ka neoplasm malignant umauma metastatic i ka ʻike mua. ʻO ka hapa nui o nā hihia ʻē aʻe o ka neoplasm maʻi hānai a me metastatic i ka wā i hoʻi hou ai ka maʻi ʻaʻai i ka mea maʻi ma hope o ka pau ʻana o ka lapaʻau mua a me ke kala ʻia no nā makahiki he nui. ʻO ka maʻi ʻaʻai umauma metastatic, ka hapanui o nā wahine akā ʻike ʻia nō hoʻi i kahi pākēneka liʻiliʻi o nā kāne, loaʻa kahi wānana maikaʻi loa me kahi ola 5 mau makahiki ma lalo o 30% e like me ka ʻike mai ka American Cancer Society Publication (Cancer Facts and Figures, 2019 ). ʻO ke ola waena waena o ka metastatic TNBC he 1 makahiki wale nō ke hoʻohālikelike ʻia me 5 mau makahiki no nā ʻano subtypes ʻelua. (ʻO Waks AG a me Winer EP, JAMA 2019)

Nā koho lapaʻau no ka maʻi ʻaʻai Metastatic umauma

Mālama ʻia ka maʻi ʻaʻai umauma metastatic me nā regimens lapaʻau like ʻole e like me nā papa like ʻole o ka chemotherapy, immunotherapy, hoʻomōhala hoʻomōhala, hormonal therapy a ke kauwela nā koho, ma o ka hoʻāʻo ʻana a me ke kaʻina hana hewa, no ka mea ʻaʻohe wehewehe pono ʻia no kēia maʻi ʻaʻai. ʻO ke koho ʻana e pili i nā mole mole o nā hunaola maʻi ʻaʻai o ka umauma, nā maʻi maʻi ʻaʻai o ka umauma i hala, ke kūlana olakino o ka mea maʻi a me kahi i laha ai ka maʻi ʻaʻai. 

Inā ua pālahalaha ka maʻi ʻaʻai o ka umauma i nā iwi, a laila me ka endocrine therapy, chemotherapy a i ʻole hoʻomōhala hoʻomōhala ʻia, mālama pū ʻia ka mea hoʻomanawanui me nā mea hoʻololi hoʻololi iwi e like me bisphosphonates. Kōkua kēia mau mea me ka mālama palliative akā ʻaʻole i hōʻike ʻia e hoʻomaikaʻi i ke ola holoʻokoʻa.  

Inā ua holomua ka maʻi ʻaʻai umauma maikaʻi i ka maʻi metastatic pae IV, mālama ʻia nā mea maʻi me ka endocrine therapy i hoʻonui ʻia me nā ʻākena e modulate a pāpā paha i nā mea loaʻa estrogen, a pale paha i ka hana ʻana o ka estrogen i ke kino. Hoʻohana ʻia ka endocrine therapy, inā maikaʻi ʻole, me ka launa pū me nā lāʻau chemotherapy a i ʻole nā ​​lāʻau i manaʻo ʻia e like me nā kaola uila kinase inhibitors a i ʻole nā ​​lāʻau e kuhikuhi ana i nā wahi kikoʻī kikoʻī kūloko, e pili ana i ka molekole a me nā genomic ʻano o ka maʻi ʻaʻai.

No ka maikaʻi ʻole o ka hormone, HER2 maikaʻi, ka maʻi ʻaʻai umauma metastatic, kahi koho lapaʻau nui ʻo ia ka HER2 i hoʻomoʻa ʻia i nā lāʻau ʻohola antibody a i ʻole nā ​​mea hoʻopale mole liʻiliʻi. Hoʻohui ʻia kēia mau mea me nā lāʻau chemotherapy ʻē aʻe.

Eia nō naʻe, no nā maʻi maʻi metastatic TNBC me ka wānana maikaʻi ʻole, ʻaʻohe o nā koho lapaʻau i wehewehe ʻia. Hoʻokumu ʻia ia i ke alo o nā hoʻololi nui ʻē aʻe i kēia subtype o ka maʻi ʻaʻai. I ke ʻano o nā maʻi ʻaʻai BRCA mutant, mālama ʻia lākou me nā mea hoʻopuka poly-ADP ribose (PARP). Inā loaʻa i kēia mau maʻi ʻākoʻikoʻi nā kikoʻī pale, hiki iā lākou ke mālama ʻia me nā lāʻau immunotherapy e like me nā mea hoʻopaneʻe pale pale pale. ʻĒ aʻe, mālama ʻia kēia mau mea maʻi me nā koho chemotherapy hōʻeuʻeu loa e like me nā lāʻau platinum (Cisplatin, Carboplatin), adriamycin (Doxorubicin), nā lāʻau ʻauhau (Paclitaxel), nā mea hoʻokipa topoisomerase (Irinotecan, Etoposide) a me nā ʻano mea like ʻole like ʻole o kēia mau mea, e kāohi ka laha ana o ka mai. Hoʻohana ʻia ka chemotherapy no ka hoʻomaʻamaʻa ʻana i ka maʻi ʻaʻai umauma metastatic akā nui loa ka ʻona a me kahi hopena maikaʻi ʻole i ka maikaʻi o nā ola.

Pono no nā ʻōlelo aʻoaʻo pilikino pilikino no nā maʻi maʻi maʻi

ʻO kahi hōʻailona maʻi ʻaʻai iā ia iho kahi hanana hoʻololi e pili ana me ka hopohopo no ka huakaʻi lapaʻau e hiki mai ana a me ka makaʻu i ka maopopo ʻole o ka hopena. Ma hope o ka ʻike ʻia me ka maʻi ʻaʻai, hoʻonāukiuki ʻia nā mea maʻi e hana i nā loli ke ola i manaʻo ʻia e hoʻomaikaʻi i ko lākou olakino a me ko lākou olakino, hoʻemi i ka weliweli o ka hoʻi hou ʻana, a hoʻemi i nā hopena ʻaoʻao o kā lākou lapaʻau chemotherapy. I ka manawa pinepine, hoʻomaka lākou i ka hoʻohana ʻana i nā mea hoʻopiha papaʻai me ka lōkahi, me kā lākou mālama ʻana i ka chemotherapy, e kōkua ai i ka hōʻemi ʻana i nā hopena ʻino loa a hoʻomaikaʻi i ko lākou olakino olakino. Aia nā hōʻike o 67-87% o nā maʻi maʻi ʻaʻai e hoʻohana i nā mea hoʻopihapiha diet post post diagnosis. (ʻO Velicer CM et al, J Clin. ʻO Oncol., 2008)  

Eia naʻe, ʻaʻohe pilikino nā ʻōlelo hānai a me nā papaʻai no nā mea maʻi ʻaʻai i kēia lā. ʻOiai nā holomua o nā genomics, metabolomics, proteomics i hoʻomaikaʻi i ko mākou ʻike i nā ʻano maʻi ʻaʻai a me ka hiki ʻana i ke ʻano o ka hoʻomaʻemaʻe ʻana, ke alakaʻi ʻana i ka meaʻai inā he mana nui kekahi. ʻAʻole hoʻokumu ʻia ke alakaʻi meaʻai i ke ʻano maʻi ʻaʻai kikoʻī a me nā ʻano genetiko o ka maʻi ʻaʻai, a i ʻole ke ʻano o ka lāʻau i hāʻawi ʻia i ka mea maʻi. ʻO nā kulekele laulā no ka meaʻai / papaʻai e like me ka ʻōlelo a ka American Cancer Society e komo pū ana: 

• Mālama i kahi kaupaona olakino; 
• Hāpai i kahi nohona ola kino; 
• Ke hoʻopau nei i ka papaʻai olakino me ke koʻikoʻi i nā kumuwaiwai mea kanu; a 
• Ka palena ʻana i ka inu lama. 

ʻO nā koho lapaʻau no nā maʻi ʻokoʻa ʻokoʻa i hōʻike ʻia a koi ʻia e nā ʻōkuhi kaiāulu like ʻole e like me ka National Comprehensive Cancer Network (NCCN) a i ʻole American Cancer Society (ACS). Hoʻokumu ʻia nā hōʻike i loaʻa no nā lāʻau i nā hoʻokolohua hoʻokolohua kaulike nui ʻia (RCTs). Hoʻonohonoho ʻia nā ʻano lapaʻau he nui i nā ʻano genomic maʻi ʻaʻai. ʻOiai kēlā, no ka nui o nā maʻi ʻaʻai e like me ka metastatic TNBC, ʻaʻohe alakaʻi maʻamau a me nā regimens lapaʻau e ʻike ʻia he maikaʻi. Hoʻomau ʻia ka mālama ʻana no kēia subtype i ka hoʻokolokolo a me nā hoʻokokoke hewa.  

Eia nō naʻe, ʻaʻohe mea e pili ana i nā kulekele e pili ana i ka pilikino / nā papaʻai pilikino. Aia ka hapa o nā RCT e hana i nā hōʻike no ka hoʻomohala ʻana i nā ʻōlelo ʻaiaola a me nā alakaʻi papaʻai e hoʻopiha ai i nā ʻano maʻi ʻaʻai like ʻole a me nā mālama ʻana. He āpau nui kēia a mākou e mālama nei i ka maʻi ʻaʻai i kēia lā. I loko nō o ka hoʻonui ʻana o ka ʻike o ka pilina o nā ʻenekua, ʻo nā paʻakikī o nā hana nutrient a me nā pilina e paʻakikī e kamaʻilio kūpono ma o ka hoʻolālā noiʻi RCT hoʻokahi. (Blumberg J et al, Nutr. Rev, 2010)  

Ma muli o kēia palena, ʻokoʻa mau ka pae o ka hōʻike no ke kākoʻo ʻana i ka meaʻai a me ka hilinaʻi no ka wehewehe ʻana i nā pono meaʻai / meaʻai no nā maʻi maʻi maʻi maʻi mai ka mea e pono ai no ka loiloi lāʻau. Eia hou, ʻo ke alakaʻi ʻana i ka meaʻai/ʻai ʻaʻole e like me nā lāʻau lapaʻau he kūlohelohe, palekana a pili pū me nā hopena haʻahaʻa a liʻiliʻi i ka hapa nui o nā hihia. Eia naʻe, hoʻopilikino i nā ʻōlelo aʻoaʻo meaʻai no ka pōʻaiapili kikoʻī o Ka maʻi 'aʻai ʻano a me ka lapaʻau e pili ana i ke ala ʻepekema a me kahi kumu i kākoʻo ʻia e ka ʻikepili hoʻokolohua, ʻoiai ʻaʻole like me nā hōʻike i hoʻokumu ʻia RCT, hiki ke hāʻawi i ke alakaʻi maikaʻi aʻe no nā maʻi a hoʻonui i ka mālama ʻana i ka maʻi kanesa.

ʻOiai he heterogeneity ʻoiai i nā maʻi ʻino a me nā mālama ʻana no nā neoplasms malignant metastatic o ka ʻano kiko like, pono e hoʻopilikino ʻia i nā ʻōlelo ʻaiaola. ʻO ka meaʻai kūpono kūpono a me nā mea nui aku e hōʻalo i nā ʻano kikoʻī a i ka wā o ka mālama ʻana hiki ke kōkua i ka hoʻomaikaʻi ʻana i nā hopena.

Nā kōkua o ke kōkua pilikino pilikino / papaʻai (nā meaʻai a me nā mea kōkua) no ka maʻi ʻaʻai Metastatic umauma

E like me nā ʻano maʻi a me nā mālama ʻana no ka maʻi ʻaʻai umauma metastatic i loli loa e pili ana i ka subtype mua o ka maʻi, ʻaʻole nō e like ka nui o nā koi no ke kākoʻo pono / meaʻai (nā meaʻai a me nā mea hoʻopiha). E kaukaʻi ʻia ia i nā ʻano genetiko o ka maʻi ʻaʻai umauma metastatic a me ke ʻano o ka mālama ʻana i loaʻa. No laila nā kumu kūlohelohe o ka maʻi, nā ʻano ʻē aʻe o nā mea maʻi pākahi e pili ana i ka papa kuhikuhi o ko lākou kino (BMI) e nānā i nā pae momona, nā ʻano nohona e like me ka hoʻoikaika kino, ka ʻona ʻana a me nā mea ʻē aʻe e lilo i mea nui i ka hoʻolālā ʻana i ka pilikino. hiki ke kākoʻo a kūpono i ka hoʻohaunaele ʻana i ka maʻi ʻaʻai i kēlā me kēia pae o ka maʻi.  

ʻO ka mea nui o ka hāʻawi ʻana i nā meaʻai pilikino / alakaʻi pilikino i hoʻonohonoho ʻia i ka maʻi ʻaʻai kikoʻī a me ka mālama ʻana, no nā mea maʻi me nā neoplasms malignant umauma metastatic hiki ke hāʻawi i nā pono aʻe: (Wallace TC ma, J. o Amer. ʻO Coll o Nutr., 2019)

1. Hoʻonui i ka ikaika a me ka palekana o ka mea hoʻomanawanui me ka ʻole o ka hoʻopilikia ʻana i ka pono o ka lāʻau.
2. Kōkua me ka hoʻēmi ʻana i nā ʻaoʻao a me nā hopena.
3. Kōkua me ka hoʻomaikaʻi ʻana i ka hopena o ka hoʻomaʻamaʻa mau e ke koho ʻana i nā meaʻai a me nā mea hoʻopihapiha i hiki ke synergize me ke ʻano hana o ka hana hoʻomau ʻana ma o ka modulate ʻana i nā ala kūpono, a i ʻole ka pāpā ʻana i nā ala kūʻē kūʻē.
4. Hōʻalo i nā meaʻai a me nā mea hoʻopihapiha i hiki ke hoʻopilikia i ka mālama mau ʻana ma o ka launa ʻana o ka lāʻau nutrient i hiki ke hoʻohaʻahaʻa i ka hopena a hoʻonui paha i ka lāʻau o ka lāʻau.

Nā laʻana o ka pilikino pilikino / Meaʻai (Meaʻai a me nā Mea Hoʻohui) no Metastatic umauma Ka maʻi ʻaʻai

ʻO nā papaʻai / meaʻai (nā meaʻai a me nā mea hoʻopiha) nā ʻōlelo aʻoaʻo no ka metastatic hormone maikaʻi maʻi maʻi ʻaʻai e hoʻomau i ka endocrine therapy e like me Tamoxifen e ʻokoʻa loa ia mai nā mea maʻi maʻi umauma metastatic umauma maʻi.  

Nā laʻana o nā meaʻai / Pākuʻi e hōʻalo inā ma ka mālama ʻana me nā Estrogen Modulator

No nā mea maʻi ma nā modulator estrogen, kekahi mau laʻana o nā meaʻai a me nā mea hoʻopihapiha e pono ai lākou e hōʻalo i hiki ke hoʻopilikia i kā lākou mālama endocrine a me nā kumu ʻepekema i ʻōlelo ʻia ma lalo:  

Curcumin 

Curcumin, ka mea hana mai ka curry spice turmeric, kahi mea kōkua kūlohelohe i kaulana i waena o nā mea maʻi ʻaʻai a me nā mea ola no kāna kūʻē i ke kanesa a me nā anti-inflammatory waiwai. No laila, ʻo ka likelihood o nā mea maʻi maʻi umauma e lawe nei iā Curcumin ʻoiai kiʻekiʻe ʻo Tamoxifen therapy. 

Hoʻopili ʻia ka lāʻau oral Tamoxifen i loko o ke kino i loko o nā metabolite hana lāʻau ma o ka cytochrome P450 enzymes i ke akepaʻa. ʻO Endoxifen ka metabolite hana ʻo Tamoxifen, ʻo ia ka mea nui waena o ka pono o tamoxifen therapy (ʻO Del Re M et al, ʻo Pharmacol Res., 2016). Ua hōʻike ʻia kahi noiʻi noiʻi prospective prospective (EudraCT 2016-004008-71 / NTR6149) mai ka Erasmus MC Cancer Institute ma Netherlands, ua hōʻike i kahi pilina maikaʻi ʻole ma waena o Curcumin a me Tamoxifen i nā maʻi maʻi maʻi hānai (Hussaarts KGAM et al, Nā maʻi ʻaʻai (Basel), 2019). Ua hōʻike nā hopena i ka hoʻoliʻiliʻi o ka metabolite hana Endoxifen i hōʻemi ʻia i kahi ʻano helu i ka wā i lawe ʻia ai ʻo Tamoxifen me Curcumin supplement.  

ʻAʻole hiki ke mālama ʻia nā haʻawina e like me kēia, ʻoiai ma kahi helu liʻiliʻi o ka umauma Ka maʻi 'aʻai nā mea maʻi, a hāʻawi i kahi akahele no nā wahine e lawe ana i ka tamoxifen e koho i nā mea hoʻohui kūlohelohe a lākou e lawe pono ai, ʻaʻole e hoʻopilikia i ka hopena o ka lāʻau maʻi maʻi ma kekahi ʻano. Ma muli o kēia hōʻike, ʻaʻole ʻo Curcumin ka mea hoʻohui kūpono e lawe pū me Tamoxifen. Akā naʻe, ʻaʻole kēia manaʻo e pale loa ʻia ka curcumin ma ke ʻano he mea ʻala a me ka mea ʻono i ka curries.

DIM (diindolylmethane) Pākuʻi  

ʻO kahi mea kōkua maʻamau a hoʻohana pinepine ʻia i waena o nā mea maʻi maʻi umauma ʻo DIM (diindolylmethane), kahi metabolite o I3C (Indole-3-carbinol), i loaʻa ma lāʻau lau e like me broccoli, cauliflower, kale, cabbage, brussel sprouts. Hiki ke hoʻokumu ʻia kēia kaulana o DIM ma nā noiʻi haukapila i hōʻike ʻia i ka hoʻohana nui ʻana o nā mea kanu kolio i loko o ka papaʻai / mea hānai e pili nui me ka 15% haʻahaʻa o ka maʻi ʻaʻai umauma. (Liu X et al, umauma, 2013) Eia nō naʻe, kahi randomized, blind-blind, placebo kāohi hoʻokolohua hoʻopaʻa haʻawina i hoʻāʻo i ka hoʻohana o Pākuʻi DIM me Tamoxifen i nā maʻi maʻi ʻaʻai umauma, ua hōʻike i ke ʻano weliweli o ka tamoxifen hana metabolite hoʻemi ʻana, a laila hiki i ka hiki ke hōʻemi i ka hopena o ka endocrine therapy. (NCT01391689) (Thomson CA, Breast Cancer Res. Hana., 2017).

ʻOiai ke hōʻike nei nā ʻike maʻi i ke ʻano o ka launa pū ma waena o DIM a me tamoxifen, ʻo nā mea maʻi maʻi umauma ʻoiai ʻo tamoxifen therapy e hele ma ka ʻaoʻao o ke akahele a hōʻole i ka lawe ʻana i ka waihona DIM. ʻO kahi papaʻai mea kanu mea ʻai i waiwai i nā mea kanu kolio hiki ke hāʻawi i ka pono e pono ai ma mua o ka lawe ʻana i kahi waihona o DIM i kēia ʻano.

ʻO nā meaʻai kūpono a makemake ʻia no ka maʻi hānai Metastatic Breast

Nui nā meaʻai a me nā mea hoʻopili e pili ana me ka hoʻomaikaʻi ʻana i nā hopena no nā mea maʻi maʻi umauma metastatic. Ua hōʻike ʻia kahi meta-analysis o nā noiʻi prospective he nui a me nā RCT e nā mea noiʻi mai Institut Curie i Palani e pili ana kahi papaʻai momona momona me ke ola ʻoi aku ka maikaʻi. Eia kekahi, kahi papaʻai i waiwai i nā mea hoʻomaʻemaʻe kino mai nā huaʻai a me nā mea kanu, hoʻemi i ka makaʻu o ke kanesa hou. A, ʻo ka papaʻai olakino me nā meaʻai mea kanu e pili ana me ka hoʻomaikaʻi ʻana i ke ola āpau a me ka makaʻu o ka make. (Maumy L et al, Ka maʻi ʻaʻai kau, 2020)

ʻO kahi noiʻi i paʻi ʻia ma mua o kēia makahiki i hoʻāʻo i ka hopena o kaʻai ketogenic / meaʻai i ke ola o nā maʻi maʻi maʻi umauma. Ua ʻike lākou i kaʻai ketogenic me nā chemotherapy hoʻomau e hoʻomaikaʻi i ke ola holoʻokoʻa me ka ʻole o nā hopena ʻē aʻe i nā maʻi. (Khodabakhshi A, Nutr. Kanesa, 2020) ʻO kaʻai ketogenike kahi papaʻai low-carbohydrate nui loa e manaʻo e hāpai i ka metabolism o nā momona i loko o nā kino ketone (ma mua o nā carbohydrates i ka glucose) e hāʻawi i ke kumu nui o ka ikehu no ke kino. Hiki i nā hunaola maʻamau i loko o kā mākou kino ke hoʻololi i ka hoʻohana ʻana i nā kino ketone no ka ikehu, akā ʻaʻole hiki i nā hunaola maʻi ʻaʻai ke hoʻohana pono i nā kino ketone no ka ikehu ma muli o kahi metabolism tumo maʻamau. ʻO kēia ka mea e maʻalahi ai nā hunaola tumora a ʻo ka mea hoʻohui, hoʻemi ke kino ketone i ka angiogenesis tumo a me ka mumū ʻoiai e hoʻonui ana i ka make o ka pūpū tumora. (Wallace TC ma, J. o Amer. ʻO Coll o Nutr., 2019)

No ka mea pono e kau ʻia nā pahuhopu therapeutic kikoʻī e pili ana i nā ʻano maʻi ʻaʻai a me ke ʻano o ka mālama ʻana, pono e hoʻokumu ʻia ka kikoʻī a me ka pilikino pilikino ma luna o kēlā me kēia meaʻai a me nā mea hoʻopihapiha me nā ʻano hana o ka hana ma ka pae mole mole e pili ana i nā hopena ma nā genes a me nā ala hele. (ʻO Reglero C a me Reglero G, Nutrients, 2019)

 ʻO kahi laʻana, hoʻokahi ala e pale aku ai i ka metastasis o ka maʻi ʻaʻai ka pale ʻana i ka angiogenesis, ke kupu ʻana o nā kīʻaha koko hou, kahi e pale ai i ke kūpaʻa chemotherapy. Aia nā meaʻai a me nā mea hoʻohui me ka bioactive silibinin, e like me artichoke a waiū waiū, i hōʻike ʻepekema e kāohi i ka angiogenesis. Nā ʻōlelo aʻoaʻo pilikino / papaʻai pilikino o kēia mau meaʻai / mea hoʻopiha i kēia ʻano o ka maʻi ʻaʻai umauma metastatic e hele ana i ka chemotherapy, hiki ke kōkua i ka hoʻomaikaʻi ʻana i ka maikaʻi o ka mālama ʻana a pale i ka hoʻi hou ʻana. (Binienda A, et al, Nā Anticancer Agents Med Chem, 2019)

Pēlā nō, hiki ke kālailai ʻia nā ʻano kī ʻē aʻe o ka maʻi ʻaʻai a me ka mālama ʻana e ʻike i nā meaʻai kūpono ʻepekema a me nā mea hoʻopihapiha no ka hoʻolālā pilikino pilikino no nā mea maʻi maʻi maʻi e kūlike i kā lākou ʻano maʻi ʻaʻai e like me ka maʻi ʻaʻai umauma metastatic a me ka mālama ʻana.

Panina

Ke neʻe nei nā manaʻo lapaʻau i ka pilikino e pili ana i ka genomics cancer a me nā hiʻohiʻona molecular cancer o kēlā me kēia maʻi, pono pū ka mālama ʻana i ka maʻi maʻi e neʻe i ka meaʻai kākoʻo pilikino e pili ana i ke kahua a me ke ʻano o Ka maʻi 'aʻai a me ka lapaau ana. He wahi nui ʻole kēia i hiki ke kōkua nui i ka hoʻomaikaʻi ʻana i nā hopena a me ka maikaʻi o ke ola no nā poʻe maʻi me ka maʻi kanesa umauma metastatic. I ke olakino maikaʻi, ʻaʻohe pōʻino nā meaʻai maoli a me nā mea hoʻohui. Akā, inā ʻo ka pōʻaiapili ka maʻi kanesa kahi e hana mua ai ke kino i kahi dysregulation kūloko i ka metabolism a me ka pale ʻana ma muli o ka maʻi a me ka mālama mau ʻana, ʻo nā meaʻai maoli, inā. koho pono ʻole ʻia, hiki ke hana i ka ʻino. No laila, nā meaʻai pilikino pilikino e pili ana i ka maʻi ʻaʻai (e like me ka maʻi ʻaʻai o ka umauma) a me ke ʻano lapaʻau e hiki ke kākoʻo i nā hopena i hoʻomaikaʻi ʻia a me ka maikaʻi no ka mea maʻi.

He aha nā meaʻai āu e ʻai ai a me nā mea hoʻopihapiha āu e lawe ai i hoʻoholo. Pono e hoʻoholo i kāu hoʻoholo ʻana e pili ana i ka hoʻololi ʻana i nā ʻāpana o ka maʻi ʻaʻai, ka maʻi ʻaʻai, nā lāʻau e hoʻomau nei a me nā mea hoʻopihapiha, nā maʻi āpau, nā ʻike nohona, ke kaupaona, ke kiʻekiʻe a me nā ʻano.

ʻAʻole hoʻokumu ʻia ka hoʻolālā meaʻai no ka maʻi ʻaʻai mai addon ma ka ʻimi pūnaewele. Hoʻokele ia i ka hoʻoholo ʻana iā ʻoe ma muli o ka ʻepekema molekole i hoʻokō ʻia e ko mākou ʻepekema a me nā ʻenekini polokalamu. Nānā ʻole inā ʻoe e noʻonoʻo e hoʻomaopopo i ke ʻano o nā ʻolaola biōmika kumu a i ʻole ʻole - no ka hoʻolālā meaʻai no ka maʻi ʻaʻai e pono ai ka ʻike.

E hoʻomaka I K NOWIA manawa me kāu hoʻolālā meaʻai e ka pane ʻana i nā nīnau e pili ana i ka inoa o ka maʻi ʻaʻai, ka hoʻololi ʻana o nā kūpuna, nā mālama ʻana a me nā mea hoʻopihapiha mau, nā maʻi āpau, nā ʻano, ka nohona, nā makahiki a me nā kāne.

ʻO nā mea maʻi maʻi maʻi e hana pinepine me nā mea ʻokoʻa nā hopena ʻaoʻao chemotherapy kahi e hoʻopili ai i ko lākou ola o ke ola a nānā i nā hoʻoponopono ʻokoʻa no ka maʻi ʻaʻai. Lawe ana i ka ka meaʻai kūpono a me nā mea hoʻopihapiha e pili ana i nā noʻonoʻo ʻepekema (ka hōʻalo ʻana i ka wānana a me ke koho wale ʻana) ʻo ia ka lāʻau kūlohelohe maikaʻi loa no ka maʻi ʻaʻai a me ka lāʻau e pili ana ʻaoʻao-hopenats.

• ʻO ke kōkua kūpono haʻahaʻa o Irinotecan a me Etoposide i nā maʻi me ka maʻi maʻi maʻi Metastatic Breast
• About
• Loaʻa ka kope a me ke ola ʻana i nā maʻi maʻi maʻi kala
• ʻO ke kau ʻana o ka Tumor a me ka mālama ʻana i ka maʻi ʻaʻai pilikino
• ʻO nā kumu kiʻekiʻe 3 e hana i ka Sequencing Genomic o ka maʻi ʻaʻai